Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Trial ID or NCT#
This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office